Twin Capital Management Inc. Decreases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Twin Capital Management Inc. lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,170 shares of the life sciences company’s stock after selling 1,120 shares during the period. Twin Capital Management Inc.’s holdings in Illumina were worth $1,534,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Trivant Custom Portfolio Group LLC increased its position in Illumina by 166.7% in the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after purchasing an additional 125 shares during the last quarter. Wetzel Investment Advisors Inc. purchased a new position in shares of Illumina in the 4th quarter worth $37,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after buying an additional 132 shares in the last quarter. Gradient Investments LLC increased its holdings in shares of Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter valued at about $42,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 0.6 %

NASDAQ:ILMN traded up $0.69 during midday trading on Wednesday, hitting $116.29. The stock had a trading volume of 1,314,542 shares, compared to its average volume of 2,141,152. The stock has a 50-day moving average of $109.63 and a 200 day moving average of $124.44. The company has a market capitalization of $18.52 billion, a price-to-earnings ratio of -14.27 and a beta of 1.15. Illumina, Inc. has a one year low of $89.00 and a one year high of $195.64. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.08 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 1.38 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ILMN. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research report on Wednesday, July 10th. TD Cowen decreased their price target on Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a report on Thursday, June 6th. StockNews.com began coverage on Illumina in a research report on Sunday, June 30th. They issued a “buy” rating for the company. Scotiabank cut their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 6th. Finally, Jefferies Financial Group started coverage on shares of Illumina in a report on Monday, June 3rd. They issued a “hold” rating and a $115.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.